Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Breast cancer

T-DM1 — an important agent in the history of breast cancer management

Nature Reviews Clinical Oncology volume 14, pages 651–652 (2017)Cite this article

Subjects

Updated results from the EMILIA and TH3RESA trials in patients with advanced-stage HER2-positive breast cancer confirm the overall survival benefit and favourable safety profile of T-DM1 after prolonged follow-up durations. The efficacy of T-DM1 as a second or later line of treatment indicates that HER2 is a relevant therapeutic target throughout the course of the disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).

    Article  CAS  Google Scholar 

  2. Krop, I. & Winer, E. P. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin. Cancer Res. 20, 15–20 (2014).

    Article  CAS  Google Scholar 

  3. Dieras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732–742 (2017).

    Article  CAS  Google Scholar 

  4. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).

    Article  CAS  Google Scholar 

  5. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743–754 (2017).

    Article  CAS  Google Scholar 

  6. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689–699 (2014).

    Article  CAS  Google Scholar 

  7. Krop, I. E. et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann. Oncol. 26, 113–119 (2015).

    Article  CAS  Google Scholar 

  8. Kim, S. B. et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int. J. Cancer 139, 2336–2342 (2016).

    Article  CAS  Google Scholar 

  9. Baselga, J. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J. Clin. Oncol. 32, 3753–3761 (2014).

    Article  CAS  Google Scholar 

  10. Baselga, J. et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin. Cancer Res. 22, 3755–3763 (2016).

    Article  CAS  Google Scholar 

  11. Loganzo, F. et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol. Cancer Ther. 14, 952–963 (2015).

    Article  CAS  Google Scholar 

  12. Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347–356 (2011).

    Article  CAS  Google Scholar 

  13. Müller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl Med. 7, 315ra188 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

The work of O.M-F. and E.P.W. at Dana-Farber Cancer Institute is supported by research funding from Genentech.

Author information

Authors and Affiliations

  1. Otto Metzger-Filho and Eric P. Winer are at the Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.,

    Otto Metzger-Filho & Eric P. Winer

Authors
  1. Otto Metzger-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric P. Winer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Metzger-Filho.

Ethics declarations

Competing interests

E.P.W. has received honoraria for his consultant role for Genentech. O.M-F. declares no competing interests.

Related links

Related links

FURTHER INFORMATION

US National Institutes of Health ClinicalTrials.gov database

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Metzger-Filho, O., Winer, E. T-DM1 — an important agent in the history of breast cancer management. Nat Rev Clin Oncol 14, 651–652 (2017). https://doi.org/10.1038/nrclinonc.2017.123

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.123

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer